Achillion Could be Major Hepatitis C Market Player

PropThink reported that Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) may have been overlooked as a participant in the hepatitis C market, which is worth approximately $20 billion.

As quoted in the market news:

It is too early to count Achillion out as an important player in the [hepatitis C] market. The company’s clinical trial data is more robust than what its share price would have you believe, and the risk/reward profile is favorable. Protease inhibitors do have a role to play in the treatment of hepatitis C, and with a market capitalization of under $600 million and several upcoming catalysts, Achillion’s shares are well positioned for a rally. With several different options strategies to mitigate risk, investors can customize their positions to meet their own levels of risk-tolerance. Achillion’s best days are ahead of it, and risk-tolerant investors who add to or initiate positions in Achillion at this point in time are likely to be rewarded for their conviction.

Click here to read the full PropThink report.